| Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension. | |
| | |
MedLine Citation:
|
PMID: 21695644 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. Because of the heterogeneous group of disorders, the therapeutic approach and response often depends on the underlying disease. In many of these conditions, there is evidence that cyclic nucleotide signaling and specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class of pulmonary vasodilators in adults. Studies are now under way to evaluate the utility, efficacy, and safety of such therapies in infants with pulmonary hypertension. |
| | |
Authors:
|
Kathryn N Farrow; Robin H Steinhorn |
Related Documents
:
|
2581524 - Leukocyte tubuloreticular inclusions in reye's syndrome. 17762614 - Recognition and management of macrophage activation syndrome in juvenile arthritis. 22067424 - Prognostic value of pulmonary dead space in patients with the acute respiratory distres... 6757284 - Pemphigus foliaceus: a case with serologic features of senear-usher syndrome and other ... 3791674 - Distal 11q monosomy. the typical 11q monosomy syndrome is due to deletion of subband 11... 9678694 - Nonasthmatic case of churg-strauss syndrome with rapidly progressive glomerulonephritis. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Handbook of experimental pharmacology Volume: - ISSN: 0171-2004 ISO Abbreviation: Handb Exp Pharmacol Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-06-22 Completed Date: 2011-09-20 Revised Date: 2012-05-11 |
Medline Journal Info:
|
Nlm Unique ID: 7902231 Medline TA: Handb Exp Pharmacol Country: Germany |
Other Details:
|
Languages: eng Pagination: 251-77 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, Division of Neonatology, Northwestern University Feinberg School of Medicine, 310 E. Superior St., Morton 4-685D, Chicago, IL 60611, USA. k-farrow@northwestern.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Humans Infant Infant, Newborn Persistent Fetal Circulation Syndrome / drug therapy*, etiology Phosphodiesterase Inhibitors / therapeutic use* Phosphoric Diester Hydrolases / physiology |
| Grant Support | |
ID/Acronym/Agency:
|
HL086715/HL/NHLBI NIH HHS; HL54705/HL/NHLBI NIH HHS; R01 HL054705/HL/NHLBI NIH HHS; R01 HL054705-14/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Phosphodiesterase Inhibitors; EC 3.1.4.-/Phosphoric Diester Hydrolases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phosphodiesterase inhibition in heart failure.
Next Document: Role of phosphodiesterases in adult-onset pulmonary arterial hypertension.